| 10/04/26 | 15:30:00 | 10 Apr 2026 | | Director/PDMR Shareholding |
| 10/04/26 | 07:00:04 | 10 Apr 2026 | | Transaction in Own Shares |
| 09/04/26 | 15:30:01 | 9 Apr 2026 | | Director/PDMR Shareholding |
| 09/04/26 | 07:00:03 | 9 Apr 2026 | | Transaction in Own Shares |
| 08/04/26 | 07:00:09 | 8 Apr 2026 | | Exdensur approved for CRSwNP in China |
| 08/04/26 | 07:00:04 | 8 Apr 2026 | | Transaction in Own Shares |
| 07/04/26 | 07:00:05 | 7 Apr 2026 | | Transaction in Own Shares |
| 02/04/26 | 07:00:02 | 2 Apr 2026 | | Transaction in Own Shares |
| 01/04/26 | 15:30:01 | 1 Apr 2026 | | Director/PDMR Shareholding |
| 01/04/26 | 15:00:00 | 1 Apr 2026 | | Total Voting Rights |
| 01/04/26 | 07:00:08 | 1 Apr 2026 | | ViiV completes changes to minority shareholding |
| 01/04/26 | 07:00:05 | 1 Apr 2026 | | Transaction in Own Shares |
| 31/03/26 | 07:00:03 | 31 Mar 2026 | | Transaction in Own Shares |
| 30/03/26 | 07:05:00 | 30 Mar 2026 | | Bepirovirsen accepted for review in China |
| 30/03/26 | 07:00:13 | 30 Mar 2026 | | Exdensur approved for severe asthma in China |
| 30/03/26 | 07:00:07 | 30 Mar 2026 | | Transaction in Own Shares |
| 27/03/26 | 07:00:08 | 27 Mar 2026 | | Bepirovirsen accepted for review by the EMA |
| 27/03/26 | 07:00:03 | 27 Mar 2026 | | Transaction in Own Shares |
| 26/03/26 | 07:00:04 | 26 Mar 2026 | | Transaction in Own Shares |
| 25/03/26 | 15:30:00 | 25 Mar 2026 | | Director/PDMR Shareholding |
| 25/03/26 | 13:00:00 | 25 Mar 2026 | | Notice of AGM |
| 25/03/26 | 07:00:05 | 25 Mar 2026 | | Transaction in Own Shares |
| 24/03/26 | 07:00:07 | 24 Mar 2026 | | Transaction in Own Shares |
| 23/03/26 | 15:30:01 | 23 Mar 2026 | | Director/PDMR Shareholding |
| 23/03/26 | 15:00:00 | 23 Mar 2026 | | Admission to Trading |
| 23/03/26 | 07:00:13 | 23 Mar 2026 | | GSK Lung Cancer ADC Gets Japan Orphan Drug Status |
| 23/03/26 | 07:00:06 | 23 Mar 2026 | | Transaction in Own Shares |
| 20/03/26 | 07:00:06 | 20 Mar 2026 | | Transaction in Own Shares |
| 19/03/26 | 12:00:00 | 19 Mar 2026 | | Lynavoy (linerixibat) approved by US FDA |
| 19/03/26 | 07:00:09 | 19 Mar 2026 | | Transaction in Own Shares |
| 18/03/26 | 15:30:01 | 18 Mar 2026 | | Director/PDMR Shareholding |
| 18/03/26 | 07:00:06 | 18 Mar 2026 | | Transaction in Own Shares |
| 17/03/26 | 15:30:01 | 17 Mar 2026 | | Director/PDMR Shareholding |
| 17/03/26 | 07:00:05 | 17 Mar 2026 | | Transaction in Own Shares |
| 16/03/26 | 07:00:09 | 16 Mar 2026 | | Transaction in Own Shares |
| 13/03/26 | 10:31:23 | 13 Mar 2026 | | US FDA approves Arexvy for adults 18-49 AIR |
| 13/03/26 | 07:00:03 | 13 Mar 2026 | | Transaction in Own Shares |
| 12/03/26 | 15:30:00 | 12 Mar 2026 | | Director/PDMR Shareholding |
| 12/03/26 | 07:00:05 | 12 Mar 2026 | | Transaction in Own Shares |
| 11/03/26 | 07:00:03 | 11 Mar 2026 | | Transaction in Own Shares |
| 10/03/26 | 07:00:06 | 10 Mar 2026 | | Transaction in Own Shares |
| 09/03/26 | 15:00:00 | 9 Mar 2026 | | Board Committee Change |
| 09/03/26 | 07:00:14 | 9 Mar 2026 | | GSK and Alfasigma agree global linerixibat rights |
| 09/03/26 | 07:00:07 | 9 Mar 2026 | | Transaction in Own Shares |
| 06/03/26 | 14:21:19 | 6 Mar 2026 | | Filing of GSK plc 2025 Annual Report on Form 20-F |
| 06/03/26 | 07:00:05 | 6 Mar 2026 | | Transaction in Own Shares |
| 05/03/26 | 10:00:00 | 5 Mar 2026 | | GSK publishes Annual Report 2025 |
| 05/03/26 | 07:00:05 | 5 Mar 2026 | | Transaction in Own Shares |
| 04/03/26 | 15:30:00 | 4 Mar 2026 | | Director/PDMR Shareholding |
| 04/03/26 | 07:00:05 | 4 Mar 2026 | | Transaction in Own Shares |